Their use has tremendously increased due to their favorable profile but they are also the focus of attention because of their side effect of euglycemic diabetic ketoacidosis (euDKA), which is challenging to diagnose because of its rarity and normal or mildly elevated blood glucose levels. SGLT2i...
综上所述,SGLT-2i可通过多种途径使酮体生成增加、清除率下降,导致酮体蓄积而引发酮症酸中毒,由于SGLT-2i可增加尿糖排泄,患者在发生酮症酸中毒时,血糖往往不超过13.9mmoL/L,被称为“血糖不高的DKA”,容易被忽视或漏诊。建议在使用SGLT-2i期间,若患者出现如恶心...
使用 SGLT2i 时发生 DKA 的患者症状不典型,血糖通常不超过 13.9 mmol/L,为非高血糖性 DKA,也称血糖正常的酮症酸中毒(euDKA)。 有Meta 分析检索了 PubMed 和 EMBASE 数据库 2010 年 1 月至 2020 年 8 月的病例报告和临床试验中接...
Euglycemic diabetic ketoacidosis (EuDKA) secondary to Sodium-glucose co-transporter-2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2D) is a rare but increasingly reported phenomenon. Not much is known about the burden of EuDKA in patients on SGLT2i or the associated factors. This retrosp...
And in May, the US Food and Drug Administration (FDA) issued asimilar warningabout the drug class, noting 20 cases of euglycemic DKA linked to SGLT2-inhibitor use — most of those affected had type 2 diabetes. SGLT2 inhibitors are a new class of drug for the treatment of type 2 diabete...
SGLT2i可能会引起血酮升高,轻度血酮升高是SGLT2i可能的心肾保护机制之一,但需关注DKA发生风险。值得注意的是,SGLT2i治疗中发生的DKA约70%为血糖正常型酮症酸中毒(euglycemic diabetic ketoacidosis,euDKA)。SGLT2i增加尿糖排泄降低血糖,胰岛素分泌减少和胰高血糖素分泌增加;特别是在并发疾病和(或)代谢应激(如手术、...
Genital mycotic infections associated with SGLT2 inhibitor use are typically mild, and uncomplicated infections can be treated with oral or topical antifungals.69,70 SGLT2 inhibitors have been associated with an increased risk of euglycemic diabetic ketoacidosis (DKA).71,72 An observational study of ...
[29], SGLT2i therapy may be inappropriate in patients at risk for genitourinary tract infections, euglycemic DKA and possibly (demonstrated solely for canagliflozin) lower-extremity amputations and fractures. SGLT2is should be prescribed in these individuals at risk with great caution. Doctors should...
In DAPA-CKD, no cases of DKA were reported with dapagliflozin treatment; however, all patients should receive counseling regarding “sick day” medication management upon SGLT2 inhibitor prescription. SGLT2 Inhibitors in Heart Failure Subsequent to the consistent benefits in heart failure hospitalization...
Several key milestones, including CV protection and improved survival in EMPA-REG OUTCOME [1], risk of euglycemic diabetic ketoacidosis (euDKA) with SGLT2i class [2] and lower limb amputations in the CANVAS program [3], have been unexpected findings. Such important unexpected outcomes have ...